Showing results (91-100 of 130) with videos related to
Sort By:
Pageof 13
American Journal of Respiratory and Critical Care Medicine|June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension StudyClaire Wainwright, Susanna A McColley, Paul McNally, et al.American Journal of Respiratory Cell and Molecular Biology|May 12, 2026
Metabolic alterations in cystic fibrosis lymphocyte memory accompanies restoration of CFTR functionMilene T Saavedra, Noel M Rysavy, Katie E Poch, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 4, 2025
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatmentEdith T Zemanick, Bonnie Ramsey, Dorota Sands, et al.Plos One|September 26, 2024
Impact of sinus surgery in people with cystic fibrosis and chronic rhinosinusitis in the era of highly effective modulator therapy: Protocol for a prospective observational studyChristine M Liu, Jakob L Fischer, Jeremiah A Alt, et al.Plos One|September 9, 2016
Extremes of Interferon-Stimulated Gene Expression Associate with Worse Outcomes in the Acute Respiratory Distress SyndromeJerry A Nick, Silvia M Caceres, Jennifer E Kret, et al.The Lancet. Respiratory Medicine|January 5, 2025
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trialJordana E Hoppe, Ajay S Kasi, Jessica E Pittman, et al.American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World StudyCarlo Castellani, Pedro Mondejar-Lopez, Fredrick Van Goor, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 23, 2025
Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centersEmily M Godfrey, Amalia Magaret, Andrea Roe, et al.The New England Journal of Medicine|October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesDominic Keating, Gautham Marigowda, Lucy Burr, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 22, 2021
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosisNico Derichs, Jennifer L Taylor-Cousar, Jane C Davies, et al.Pageof 13